What cancer matches mean for treatment
Cancer matches refer to treatment options that align with the biological features of a person’s tumor. They arise when genomic, molecular, or clinical characteristics of a cancer indicate a particular therapy is likely to work. Identifying matches typically involves biomarker testing of tumor tissue or blood, and results help clinicians choose targeted therapies, immunotherapies, or clinical trial options. This overview explains how matches are defined, how testing is performed, how results are interpreted, and how they influence care while noting current limitations.
How testing finds cancer matches
Finding cancer matches starts with comprehensive biomarker testing. Pathologists examine tumor samples using techniques such as immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing to look for actionable alterations. Common targets include mutations in genes like EGFR, ALK, ROS1, BRAF, and tumor biomarkers such as PD-L1 or MSI status. Liquid biopsies, which analyze circulating tumor DNA, may be used when tissue is limited or to detect changes over time.
Types of cancer biomarkers used for matching
- DNA mutations: changes in oncogenes or tumor suppressor genes that drive growth.
- Gene fusions or rearrangements: abnormal joining of genes that produce targetable drivers.
- Protein expression: levels of proteins like PD-L1 or hormone receptors that affect immune or endocrine response.
- Microsatellite instability (MSI) or tumor mutational burden (TMB): features that can predict immunotherapy response.
How results are interpreted and reported
Results are usually reported as either actionable, potentially actionable, or not actionable. Actionable findings indicate a therapy with strong evidence for benefit, while potentially actionable results suggest options supported by emerging data or specific trial criteria. Variants of uncertain significance (VUS) are common; they indicate that the clinical role of a finding is unclear and often require further study or reclassification. Clinicians consider guidelines from organizations such as NCCN and ASCO when deciding which matches to pursue.
How cancer matches guide treatment decisions
When a clear match is found, treatment may involve a targeted drug, an immunotherapy regimen, or participation in a trial designed for that alteration. For example, patients with an EGFR exon 19 deletion in lung adenocarcinoma often respond well to EGFR tyrosine kinase inhibitors, while those with an ALK rearrangement may be candidates for ALK inhibitors. In colorectal cancer, BRAF V600E and RAS wild-type status can determine whether anti-EGFR therapy is appropriate. These examples illustrate how matches can direct choice, sequence, and combination strategies.
Representative associations between alterations and therapies
| Alteration | Typical Match | Context |
|---|---|---|
| EGFR exon 19 deletion in NSCLC | EGFR tyrosine kinase inhibitors | First-line therapy for advanced disease |
| ALK rearrangement in NSCLC | ALK inhibitors (e.g., alectinib, crizotinib) | Used in earlier and advanced settings |
| BRAF V600E in melanoma or colorectal cancer | BRAF inhibitors ± MEK inhibitors | Context-dependent; anti-EGFR often avoided in colorectal BRAF V600E |
| PD-L1 high (TPS ≥50%) in NSCLC | PD-1/PD-L1 inhibitors as first-line therapy | Often combined with chemotherapy |
| MSI-H or TMB-high (≥10 mut/Mb) in multiple tumor types | PD-1/PD-L1 inhibitors | Approved across cancers with MSI-H/pMMR deficiency |
Limitations and what matches do not guarantee
A cancer match does not ensure that a treatment will work for a specific person. Response depends on tumor biology, location, prior therapies, overall health, and drug access. Some alterations have multiple matched options, while others may have none approved outside of trials. In addition, acquired resistance can develop over time, requiring new testing or strategy changes. Interpretation can evolve as evidence grows, underscoring the importance of ongoing discussion with the care team.
What patients and caregivers should do next
If you are considering or have received cancer match testing, prepare for care planning by gathering pathology reports, prior treatment records, and imaging summaries. Bring these to a multidisciplinary tumor board or a molecular tumor board if available. Ask your oncologist which alterations are actionable, what options exist, and which tests might be needed to clarify uncertain findings. Decisions should balance potential benefits, side effects, convenience, and personal goals, and should revisit testing when appropriate.
Key takeaways
- Cancer matches link tumor characteristics to treatment options.
- Comprehensive biomarker testing is essential to identify matches.
- Guidelines and multidisciplinary teams help interpret and apply results.
- Matches inform but do not guarantee outcomes; shared decision-making is key.
- Retesting and clinical trial participation remain important over time.